XT2 is a potent, orally active, and selective NF-κB-inducing kinase (NIK) inhibitor with potential for the treatment of inflammatory liver diseases; it inhibits CCl4-induced ALT elevation (a key biomarker of acute liver injury) and reduces immune cell infiltration into damaged liver tissue.